Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $220.5 million.

  • Ultragenyx Pharmaceutical's Accumulated Expenses rose 1918.52% to $220.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $220.5 million, marking a year-over-year increase of 1918.52%. This contributed to the annual value of $241.0 million for FY2024, which is 2264.13% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Accumulated Expenses stood at $220.5 million, which was up 1918.52% from $180.8 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Accumulated Expenses registered a high of $241.0 million during Q4 2024, and its lowest value of $82.7 million during Q1 2021.
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Accumulated Expenses value was $170.4 million (recorded in 2022), while the average stood at $163.7 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Accumulated Expenses skyrocketed by 8707.99% in 2022 and then tumbled by 789.41% in 2024.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Accumulated Expenses stood at $145.6 million in 2021, then surged by 40.62% to $204.7 million in 2022, then decreased by 4.0% to $196.5 million in 2023, then grew by 22.64% to $241.0 million in 2024, then fell by 8.49% to $220.5 million in 2025.
  • Its Accumulated Expenses was $220.5 million in Q3 2025, compared to $180.8 million in Q2 2025 and $173.0 million in Q1 2025.